Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine.

Ítems similars

• Pharmacokinetic Evaluation of Oral Levofloxacin in Human Immunodeficiency Virus-Infected Subjects Receiving Concomitant Antiretroviral Therapy
  per: Villani, P., et al.
  Publicat: (2001)
• Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection.
  per: Goodwin, S D, et al.
  Publicat: (1994)
• Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses.
  per: Chien, S C, et al.
  Publicat: (1997)
• Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects.
  per: Chien, S C, et al.
  Publicat: (1997)
• Multiple-dose pharmacokinetics of oral zidovudine in hemophilia patients with human immunodeficiency virus infection.
  per: Morse, G D, et al.
  Publicat: (1990)